The psychopharmacology algorithm project at the harvard south shore program: An update on bipolar depression

Harvard Review of Psychiatry

Volumn 18, Issue 1, 2010, Pages 36-55

  Ansari, Arash ^a   Osser, David N ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Algorithms; Antidepressive agents; Bipolar depression; Bipolar disorder; Electroconvulsive therapy; Lamotrigine; Lithium; Psychopharmacology; Quetiapine

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; FLUOXETINE PLUS OLANZAPINE; ICOSAPENTAENOIC ACID ETHYL ESTER; LAMOTRIGINE; LITHIUM; MODAFINIL; MOOD STABILIZER; NEUROLEPTIC AGENT; NORFLUOXETINE; OLANZAPINE; OMEGA 3 FATTY ACID; OXCARBAZEPINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADD ON THERAPY; AKATHISIA; ALGORITHM; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR II DISORDER; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES INSIPIDUS; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; HUMAN; HYPOTHYROIDISM; KIDNEY FAILURE; MANIA; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NEUROLOGIC DISEASE; PHYSICIAN; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOPHARMACOLOGY; PSYCHOSIS; RASH; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SUICIDE; TREATMENT INDICATION; WEIGHT GAIN;

ALGORITHMS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; FLUOXETINE; HUMANS; LITHIUM CARBONATE; TREATMENT FAILURE; TRIAZINES;

EID: 74949091116     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.3109/10673220903523524     Document Type: Review

References (187)

1. American Psychiatric Association. Diagnostic and statistical manual ofmental disorders. 4th ed., text rev.Washington, DC: American Psychiatric Press, 2000.
2. Silverstone T,McPherson H, Li Q, Doyle T. Deep whitematter hyperintensities in patients with bipolar depression, unipolar depression and age-matched control subjects. Bipolar Disord 2003;5:53-57
3. Cannon DM, Ichise M, Rollis D, et al.Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry 2007;62:870-877
4. Mitchell PB, Malhi GS. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord 2004;6:530-539
5. Hegerl U, Bottner AC, Holtschmidt-Taschner B, et al. Onset of depressive episodes is faster in patients with bipolar versus unipolar depressive disorder: evidence from a retrospective comparative study. J Clin Psychiatry 2008;69:1075-1080
6. Goodwin FK, Jamison KR. Manic-depressive illness, bipolar disorders and recurrent depression. 2nd ed. New York: Oxford University Press, 2007.
7. Dantzler A, Osser DN. Algorithms for the pharmacotherapy of acute depression in patients with bipolar disorder. Psychiatr Ann 1999;29:270-284
8. Hamoda HM, Osser DN. The psychopharmacology algorithm project at the Harvard South Shore program: an update on psychotic depression. Harv Rev Psychiatry 2008;16:235-247
9. Osser DN. Treatment resistant problems. In: Tupin JP, Shader RI, Harnett DS, eds. Clinical handbook of pharmacology. 2nd ed. New York: Aronson, 1988.
10. Osser DN. A systematic approach to the classification and pharmacotherapy of nonpsychotic major depression and dysthymia. J Clin Psychopharmacol 1993;13:133-144
11. Osser DN, Patterson RD. Algorithms for the pharmacotherapy of depression: part one. Dir Psychiatry 1998;18:303-318
12. Osser DN, Patterson RD. Algorithms for the pharmacotherapy of depression: part two. Dir Psychiatry 1998;18:319-336
13. Maj M, Pirozzi R, Magliano L, Fiorillo A, Bartoli L. Agitated "unipolar" major depression: prevalence, phenomenology, and outcome. J Clin Psychiatry 2006;67:712-719
14. O'Donovan C, Garnham JS, Hajek T, Alda M. Antidepressant monotherapy in pre-bipolar depression; predictive value and inherent risk. J Affect Disord 2008;107:293-298
15. Ghaemi SN, Ko JY, Goodwin FK. "Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002;47:125-134
16. Phelps J. The bipolar spectrum. In: Parker G, ed. Bipolar II disorder. Modeling, measuring, and managing. Cambridge: Cambridge University Press, 2008.
17. Ghaemi SN. Treatment of rapid-cycling bipolar disorder: are antidepressants mood destabilizers? Am J Psychiatry 2008;165:300-302
18. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4 suppl):1-50.
19. Miklowitz DJ. The role of the family in the course and treatment of bipolar disorder. Curr Dir Psychol Sci 2007;16: 192-196
20. Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007;64:419-426
21. Miklowitz DJ, Otto MW, Frank E, et al. Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry 2007;164:1340-1347
22. Reilly-Harrington NA, Deckersbach T, Knauz R, et al. Cognitive behavioral therapy for rapid-cycling bipolar disorder: a pilot study. J Psychiatr Pract 2007;13:291-297
23. Miklowitz DJ. Adjunctive psychotherapy for bipolar disorder: state of the evidence. Am J Psychiatry 2008;165:1408-1409
24. Goodwin FK, Jamison KR. Manic depressive illness. New York: Oxford University Press, 1990.
25. Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993;13:397-408.
26. Devanand DP, Polanco P, Cruz R, et al. The efficacy of ECT in mixed affective states. J ECT 2000;16:32-37
27. Daly JJ, Prudic J, Devanand DP, et al. ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disord 2001;3:95-104.
28. Medda P, Perugi G, Zanello S, Ciuffa M, Cassano GB. Response to ECT in bipolar I, bipolar II and unipolar depression. J Affect Disord 2009;118:55-59 Epub 2009 Feb 14.
29. Ciapparelli A, Dell'Osso L, Tundo A, et al. Electroconvulsive therapy inmedication-nonresponsive patients withmixed mania and bipolar depression. J Clin Psychiatry 2001;62:552-555
30. Grunhaus L, Schreiber S, Dolberg OT, Hirshman S, Dannon PN. Response to ECT in major depression: are there differences between unipolar and bipolar depression? Bipolar Disord 2002;4 suppl 1:91-93
31. Kho KH, Zwinderman AH, Blansjaar BA. Predictors for the efficacy of electroconvulsive therapy: chart review of a naturalistic study. J Clin Psychiatry 2005;66:894-899
32. Mukherjee S, Rosen AM, Caracci G, Shukla S. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 1986;43:342-346
33. Tohen M, Zarate CA Jr. Antipsychotic agents and bipolar disorder. J Clin Psychiatry 1998;59 suppl 1:38-48; discussion 49.
34. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol 1980;13:156-167
35. Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004;161: 169-171
36. McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord 2003;(5 suppl 2):20-35.
37. Post RM, Calabrese JR. Bipolar depression: the role of atypical antipsychotics. Expert Rev Neurother 2004;4(6 suppl 2):S27-33.
38. Calabrese JR, Elhaj O, Gajwani P, Gao K. Clinical highlights in bipolar depression: focus on atypical antipsychotics. J Clin Psychiatry 2005;66 suppl 5:26-33. (Pubitemid 40934071)
39. Gao K, Gajwani P, Elhaj O, Calabrese JR. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry 2005;66:1376-1385
40. Brugue E, Vieta E. Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:275-282
41. Bauer MS, Mitchner L. What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry 2004;161:3-18.
42. Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL. The Expert Consensus Guidelines for treating depression in bipolar disorder. J Clin Psychiatry 1998;59 suppl 4:73-79
43. Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 2000;57:187-190
44. Lepkifker E, Iancu I, Horesh N, Strous RD, Kotler M. Lithium therapy for unipolar and bipolar depression among the middleaged and older adult patient subpopulation. Depress Anxiety 2007;24:571-576
45. Patel NC, DelBello MP, Bryan HS, et al. Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006;45:289-297
46. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 2007;58:85-91.
47. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999;60 suppl 2:77-84; discussion 111-116
48. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients withmood disorders: a systematic review of randomized trials. Am J Psychiatry 2005;162:1805-1819
49. Aherns B, Muller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 2001;34:132-136 (Pubitemid 32701762)
50. Marangell LB, Dennehy EB, Wisniewski SR, et al. Casecontrol analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD. J Clin Psychiatry 2008;69:916-922
51. Bearden CE, Thompson PM, Dalwani M, et al. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 2007;62:7-16.
52. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007;190:359-360
53. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008;105:2052-2057
54. Cavanagh J, Smyth R, Goodwin GM. Relapse into mania or depression following lithium discontinuation: a 7-year followup. Acta Psychiatr Scand 2004;109:91-95
55. Suppes T, Baldessarini RJ, Faedda GL, Tondo L, Tohen M. Discontinuation of maintenance treatment in bipolar disorder: risks and implications. Harv Rev Psychiatry 1993;1:131-144
56. Goodwin GM. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry 1994;164:149-152
57. Baldessarini RJ, Tondo L, Faedda GL, Suppes TR, Floris G, Rudas N. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 1996;57:441-448
58. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-912
59. Severus WE, Kleindienst N, Seemuller F, Frangou S, Moller HJ, Greil W. What is the optimal serum lithium level in the long-term treatment of bipolar disorder-a review? Bipolar Disord 2008;10:231-237
60. Kleindienst N, Severus WE, Greil W. Are serum lithium levels related to the polarity of recurrence in bipolar disorders? Evidence from a multicenter trial. Int Clin Psychopharmacol 2007;22:125-131
61. Kleindienst N, Severus WE, Moller HJ, Greil W. Is polarity of recurrence related to serum lithium level in patients with bipolar disorder? Eur Arch Psychiatry Clin Neurosci 2005;255:72-74
62. Jefferson JW, Greist AH, Ackerman DL, Carroll JA. Lithium encyclopedia for clinical practice. 2nd ed. Washington, DC: American Psychiatric Press, 1987.
63. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-1360
64. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a doubleblind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26:600-609
65. Endicott J, Rajagopalan K, MinkwitzM,MacfaddenW. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol 2007;22:29-37.
66. Hirschfeld RM, Weisler RH, Raines SR, Macfadden W. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006;67:355-362
67. McElroy S, Young AH, Carlsson A, et al. A double blind, placebo controlled study with acute and continuation phase of quetiapine and paroxetine in adults with bipolar depression (EMBOLDEN II). Bipolar Disord 2008;10(suppl 1):59.
68. Young AH. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine and lithium in adults with bipolar depression. Presented at the annual meeting of the American Psychiatric Association, Washington, DC, May 2008.
69. Nolen WA, Weisler RH, Neijber A, Hellquist A, Paulsson B. Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after stabilization on quetiapine. Eur Psychiatry 2009;24 suppl 1:S595.
70. Vedantam S. A silenced drug study creates an uproar. Wash Post 2009;Mar 18.
71. Wilson D. Drug maker's e-mail released in Seroquel lawsuit. NY Times 2009;Feb 28.
72. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-235
73. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999;60:79-88.
74. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-614
75. Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997;72:145-148
76. Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999;156:1019-1023
77. Robillard M, Conn DK. Lamotrigine use in geriatric patients with bipolar depression. Can J Psychiatry 2002;47:767-770
78. Chang K, Saxena K, HoweM. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006;45:298-304.
79. Savas HA, Selek S, Bulbul F, Kaya MC, Savas E. Successful treatment with lamotrigine in bipolar depression: a study from Turkey. Aust N Z J Psychiatry 2006;40:498-500.
80. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008;10:323-333
81. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials. Br J Psychiatry 2009;194:4-9.
82. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400. (Pubitemid 36403000)
83. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013-1024 (Pubitemid 37158246)
84. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997;17:185-189
85. Bowden CL, Mitchell P, Suppes T. Lamotrigine in the treatment of bipolar depression. Eur Neuropsychopharmacol 1999;9 suppl 4:S113-7.
86. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65:432-441
87. McElroy SL, Zarate CA, Cookson J, Suppes T, Huffman RF, Greene P, et al. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry 2004;65:204-210
88. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002;63:1012-1019
89. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005;64: 1134-1138
90. Bowden CL, Calabrese JR, Ketter TA, Sachs GS, White RL, Thompson TR. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry 2006;163:1199-1201
91. Gualtieri CT, Johnson LG. Comparative neurocognitive effects of 5 psychotropic anticonvulsants and lithium. Med Gen Med 2006;8:46.
92. TohenM, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-1088
93. Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006;67:1025-1033
94. Corya SA, Perlis RH, Keck PE, et al. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry 2006;67:798-806.
95. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in non-psychotic bipolar I depression. J Clin Psychopharmacol 2008;28:13-20.
96. Ketter TA, Wang PW, Chandler RA, Culiver JL, Alarcon AM. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry 2006;18:169-172
97. McElroy SL, Suppes T, FryeMA, et al. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. J Affect Disord 2007;101:275-281
98. Dunn RT, Stan VA, Chriki LS, Filkowski MM, Ghaemi SN. A prospective, open-label study of aripiprazole mono-and adjunctive treatment in acute bipolar depression. J Affect Disord 2008;110:70-74
99. Satajovic M, Coconcea N, Ignacio RV, et al. Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, openlabel trial. J Clin Psychiatry 2008;69:41-46
100. Kemp DE, Gilmer WS, Fleck J, Straus JL, Dago PL, Karaffa M. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:574-577 (Pubitemid 46209454)
101. Sokolski KN. Adjunctive aripiprazole in bipolar I depression. Ann Pharmacother 2007;41:35-40.
102. Kemp DE, Dago PL, Straus JL, Fleck J, Karaffa M, Gilmer WS. Aripiprazole augmentation for treatment-resistant bipolar depression; sustained remission after 36 months. J Clin Psychopharmacol 2007;27:304-305 (Pubitemid 46763316)
103. Mech AW. High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes. J Clin Psychopharmacol 2008;28:240-241
104. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005;85:259-266
105. Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: a preliminary doubleblind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007;68:1840-1844
106. American College of Obstetrics and Gynecology Practice Bulletin: Clinical management guidelines for obstetriciangynecologists number 92, April 2008. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008;111:1001-1020
107. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009;360:1597-1605
108. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry 1986;143:29-34.
109. Benedetti A, Lattanzi L, Pini S, Musetti L, Dell'Osso L, Cassano GB. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord 2004;79:273-277
110. Vieta D, Cruz N, Garcia-Campayo J, et al. A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol 2008;11:445-452
111. Osser DN. Why physicians do not follow some guidelines and algorithms. Behav Health Trends 2009;21:suppl C.
112. Van Der Loos ML,Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:223-231
113. Ghaemi SN, Goodwin FK. Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use. J Affect Disord 2001;65:281-287
114. Gyulai L, Bowden CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003;28:1374-1382
115. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008;109:251-263
116. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B; Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009;166:476-488
117. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-1722
118. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006;163:232-239
119. Vieta E. Antidepressants in bipolar depression. Acta Psychiatr Scand 2008;118:335-336
120. Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 2008;118:347-356
121. Licht RW, Gijsman H, Nolen WA, Angst J. Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand 2008;118:337-346
122. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005;66:870-886
123. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-393
124. Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand 2001;104:104-109
125. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148:910-916
126. Simpson SG, DePaulo JR. Fluoxetine treatment of bipolar II depression. J Clin Psychopharmacol 1991;11:52-54
127. Amsterdam JD, Garcia-Espana F, Fawcett J, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998;18:435-440
128. Kupfer DJ, Chengappa KN, Gelenberg AJ, et al. Citalopram as adjunctive therapy in bipolar depression. J Clin Psychiatry 2001;62:985-990
129. Vieta E, Martinez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002;63:508-512
130. Amsterdam JD, Shults J, Brunswick DJ, Hundert M. Shortterm fluoxetine monotherapy for bipolar type II or bipolar NOS major depression-low manic switch rate. Bipolar Disord 2004;6:75-81.
131. FonsecaM, Soares JC, Hatch JP, Santin AP, Kapczinski F. An open trial of adjunctive escitalopram in bipolar depression. J Clin Psychiatry 2006;67:81-86
132. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006;189:124-131
133. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4:313-322
134. Amsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J Clin Psychopharmacol 1998;18:414-417 (Pubitemid 28462632)
135. Amsterdam JD, Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affect Disord 2000;59:225-229
136. Grossman F, PotterWZ, Brown EA, Maislin G. A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. J Affect Disord 1999;56:237-243
137. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002;4:207-213
138. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-1547
139. Ghaemi SN, Rosenquist KJ, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2004;161:163-165
140. Altshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry 2006;163:313-315
141. Vieta E, Gasto C, Otero A, Nieto E, Vallejo J. Differential features between bipolar I and bipolar II disorder. Compr Psychiatry 1997;38:98-101.
142. Parker G, Tully L, Olley A, Hadzi-Pavlovic D. SSRIs as mood stabilizers for bipolar II disorder? A proof of concept study. J Affect Disord 2006;92:205-214
143. Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol 2008;28:171-181
144. Goldberg JF, Nassir Ghaemi S. Benefits and limitations of antidepressants and traditional mood stabilizers for treatment of bipolar depression. Bipolar Disord 2005;7 suppl 5:3-12.
145. MacQueen GM, Trevor Young L, Marriott M, Robb J, Begin H, Joffe RT. Previous mood state predicts response and switch rates in patients with bipolar depression. Acta Psychiatr Scand 2002;105:414-418
146. Frye MA, Helleman G, McElroy SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 2009;166:164-172
147. Boerlin HL, Gitlin MJ, Zoellner LA, Hammen CL. Bipolar depression and antidepressant-induced mania: a naturalistic study. J Clin Psychiatry 1998;59:374-379
148. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord 2003;5:407-420
149. Goldberg JF, Whiteside JE. The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. J Clin Psychiatry 2002;63:791-795
150. Nolen WA, Kupka RW, Hellemann G, et al. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand 2007;115:360-365
151. El-Mallakh RS,Ghaemi SN, SagduyuK, et al. Antidepressantassociated chronic irritable dysphoria (ACID) in STEP-BD patients. J Affect Disord 2008;111:372-377 Epub 2008 Jun 20.
152. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network forMood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006;8:721-739
153. Altshuler L, Kiriakos L, Calcagno J, et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk of relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 2001;62:612-616
154. Altshuler LL, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003;160:1252-1262
155. Altshuler LL, Post RM, Hellemann G, et al. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry 2009;70:450-457
156. Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005;162:2152-2161
157. Tondo L,Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand 2003;108:4-14. (Pubitemid 36783275)
158. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapidcycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000;61:841-850
159. Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988;145: 179-184
160. Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007;9:413-425
161. Sanger TM, Tohen M, Vieta E, et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord 2003;73:155-161
162. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006;11:227-240
163. Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med 2007;357:1939-1945
164. Olfson M, Marcus S, Sackeim HA, Thompson J, Pincus HA. Use of ECT for the inpatient treatment of recurrent major depression. Am J Psychiatry 1998;155:22-29
165. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatmentresistant illness and a history of mania. Am J Psychiatry 1999;156:1164-1169
166. Fehr BS, Ozcan ME, Suppes T. Low doses of clozapine may stabilize treatment-resistant bipolar patients. Eur Arch Psychiatry Clin Neurosci 2005;255:10-14
167. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003;64:451-458
168. Chang JS, Ha KS, Young Lee K, Sik Kim Y, Min Ahn Y. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry 2006;67:461-467
169. Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv 1998;49:1029-1033
170. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91.
171. Modestin J, Dal Pian D, Agarwalla P. Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. J Clin Psychiatry 2005;66:534-538
172. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007;164:1242-1249
173. Belmaker RH. Modafinil add-on in the treatment of bipolar depression. Am J Psychiatry 2007;164:1143-1145
174. Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009;301:1148-1154
175. Keck PE, Mintz J, McElroy SL, et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006;60:1020-1022
176. Frangou S, Lewis M, McCrone P. Efficacy of ethyleicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 2006;188:46-50.
177. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564-566
178. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60.
179. Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 2007;68:1230-1236
180. Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety and efficacy of vagus nerve stimulation in treatment-resistant depression. A systematic review. J Affect Disord 2008;110:1-15.
181. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikolea JM, Kaprinis GS. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord 2005;86:1-10. (Pubitemid 40487954)
182. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: medication treatment of bipolar disorder 2000. Postgrad Med 2000 Apr;spec no:1-104.
183. Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: treatment of bipolar depression. World J Biol Psychiatry 2002;3:115-124
184. Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003;17:149-173
185. Goodwin GM, Anderson I, Arango C, et al. ECNP consensus meeting. Bipolar depression.Nice, March 2007. Eur Neuropsychopharmacol 2008;18:535-549
186. Kaspar S, Calabrese JR, Johnson G, et al. International Consensus Group on the evidence-based pharmacological treatment of bipolar I and II depression. J Clin Psychiatry 2008;69:1632-1646
187. Schiff GD, Galanter WL. Promoting more conservative prescribing. JAMA 2009;301:865-867